Muttilainen S, Butcher S J, Runeberg K, Nurminen M, Idänpään-Heikkilä I, Wahlström E, Sarvas M
Department of Bacterial Vaccine Research and Molecular Bacteriology, National Public Health Institute, Helsinki, Finland.
Microb Pathog. 1995 May;18(5):365-71. doi: 10.1006/mpat.1995.0033.
The major outer membrane protein P1 (class 1) of Neisseria meningitidis has been produced as inclusion bodies in Bacillus subtilis with the aim to develop a vaccine based on it. The protein produced in high yield in B. subtilis contained an N-terminal extension of 11 amino acid residues which was found to be necessary for expression in the production system. In the present study we asked whether or not the removal of this extension would effect the conformation of this protein in liposomes as judged by its immunogenic properties. A methionine was engineered in front of the mature P1 protein to provide a chemical cleavage site for CNBr to remove the extension. The CNBr-cleaved protein, complexed with phospholipids, elicited high titers of antibodies binding to the meningococcal cells similarly to the noncleaved protein. This suggests that the BacP1 protein can serve as an effective vaccine component irrespective of the presence, or absence, of this N-terminal extension.
脑膜炎奈瑟菌的主要外膜蛋白P1(1类)已在枯草芽孢杆菌中作为包涵体产生,目的是基于该蛋白开发一种疫苗。在枯草芽孢杆菌中高产的该蛋白含有11个氨基酸残基的N端延伸,发现其对生产系统中的表达是必需的。在本研究中,我们探讨了去除该延伸是否会如通过其免疫原性特性所判断的那样影响该蛋白在脂质体中的构象。在成熟P1蛋白前设计了一个甲硫氨酸,为溴化氰提供一个化学切割位点以去除该延伸。经溴化氰切割的蛋白与磷脂复合后,与未切割的蛋白类似,能引发高滴度的与脑膜炎球菌细胞结合的抗体。这表明无论该N端延伸是否存在,芽孢杆菌P1蛋白都可作为一种有效的疫苗成分。